Interview: Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
Address: Eli Lilly and Company (India) pvt. Ltd., Plot# 92, Sector 32, Institutional Area, Gurgaon-122001, HARYANA, INDIA ,India
Tel: 91-124-4753000, 01
Web: https://www.lillyindia.co.in/
Eli Lilly and Company established its India operations in 1993 as a Joint venture with Ranbaxy Laboratories’ Limited. After the divestiture in 2001 it was Christened Eli Lilly and Company (India) Pvt. Ltd, and is today one of the most admired companies in terms of its focus on scientific selling, unique bouquet of products and services, working environment and focus on Ethics and Compliance Lilly India provides innovative answers to the needs of the people suffering from Diabetes, Cancer, Sepsis, Osteoporosis, Cardiovascular disorders and Growth hormone deficiency.
Major Achievements of Eli Lilly and Company (India) Pvt. Ltd.
In top 25 “Great Places to Work For in India” in 2003 and 2004 in a survey conducted by ‘Great Places to Work’ Institute
In top 25 in 2003 “Best Employers in India” in a survey conducted by Hewitt Associates.
2nd Best company to work for under ‘Biotech & Pharmaceutical’ category in 2008 in a survey conducted by Great Places to Work Institute USA’.
In top 10 “Best Companies to Work for in India’ in Business Today-Mercer-TNS survey 2008. Ranked 9th overall, achieving the unique distinction of being the only Pharmaceutical Company in this list.
We strive to touch the lives of our customers by actively listening and responding to their needs with breakthrough products and medical expertise that is critical to their understanding and treatment of diseases.
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
See our Cookie Privacy Policy Here
